Aktis Oncology Inc.
AKTS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AKTS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AKTS
Aktis Oncology Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for cancer, with lead programs in Nectin-4 and B7-H3 expressing tumors.
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials for Aktis Oncology Inc..
Aktis Oncology Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for cancer, with lead programs in Nectin-4 and B7-H3 expressing tumors.
- Lead product candidate [225Ac]Ac-AKY-1189 is in clinical trials for Nectin-4 expressing tumors [sec_mda · as of 2026-08-13].
- Second candidate [225Ac]Ac-AKY-2519 is advancing toward clinical trials for B7-H3 expressing tumors [sec_mda · as of 2026-08-13].
- As of June 30, 2026, the company had cash and equivalents of $83.6M, total revenue of $3.4M, and a net loss of $24.1M [sec].
- Accumulated deficit reached $199.0 million as of June 30, 2026 [sec_mda · as of 2026-08-13].
- The company has no approved products and has not generated any revenue from product sales [sec_mda · as of 2026-08-13].
What works
- Aktis has two clinical-stage radiopharmaceutical candidates targeting validated oncology targets (Nectin-4 and B7-H3) [sec_mda · as of 2026-08-13].
- The company is building a proprietary miniprotein radioconjugate platform, which may enable differentiated targeting and pharmacokinetics [sec_mda · as of 2026-08-13].
- Cash position of $83.6M as of June 30, 2026 provides near-term funding for ongoing clinical development [sec].
What to weigh
- Aktis has an accumulated deficit of $199.0 million as of June 30, 2026 and expects operating losses to increase substantially as it advances its pipeline [sec_mda · as of 2026-08-13].
- The company has no approved products and no revenue from product sales, relying entirely on external financing to fund operations [sec_mda · as of 2026-08-13].
- Shareholders' equity is negative ($87.8M as of June 30, 2026), indicating accumulated losses exceed assets [sec].
- The company faces significant capital requirements and may need to delay or reduce programs if additional funding is not secured [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Lead candidate targets Nectin-4 expressing tumors
“advance [ 225 Ac]Ac-AKY-1189 for Nectin-4 expressing tumors”
SEC MD&A · August 13, 2026
Second candidate targets B7-H3 expressing tumors
“[ 225 Ac]Ac-AKY-2519 for B7-H3 expressing tumors”
SEC MD&A · August 13, 2026
No approved products and no product revenue
“We do not have any products approved for sale and have not generated any revenue from product sal”
SEC MD&A · August 13, 2026
Accumulated deficit as of June 30, 2026
“2026, we had an accumulated deficit of $199.0 million”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- No approved products or revenue — The company has no products approved for sale and has not generated any revenue from product sales [sec_mda · as of 2026-08-13].
- Substantial accumulated deficit — Accumulated deficit of $199.0 million as of June 30, 2026, with net losses expected to increase [sec_mda · as of 2026-08-13].
- Negative shareholders' equity — Shareholders' equity was -$87.8M as of June 30, 2026, indicating liabilities exceed assets [sec].
- Dependence on external financing — The company will require additional funding to continue operations and may need to delay or reduce programs if capital is not raised [sec_mda · as of 2026-08-13].
What to watch
- Clinical data updates for [225Ac]Ac-AKY-1189 in Nectin-4 expressing tumors [sec_mda · as of 2026-08-13].
- Initiation of clinical trials for [225Ac]Ac-AKY-2519 in B7-H3 expressing tumors [sec_mda · as of 2026-08-13].
- Progress of IND-enabling studies for other pipeline programs [sec_mda · as of 2026-08-13].
- Any financing or partnership announcements to extend cash runway [sec_mda · as of 2026-08-13].
Sources: SEC MD&A · Generated August 24, 2026 · How we verify sources →
Run Aktis Oncology Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aktis Oncology Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
31.5 months
D/E 0.15 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
0 buys · 9 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
66
Total value held
$463.7M
| Holder | Shares | Value |
|---|---|---|
| mpm bioimpact llc | 4,835,872 | $86.5M |
| janus henderson group plc | 2,908,534 | $52.0M |
| wellington management group llp | 2,317,044 | $41.5M |
| blackrock, inc. | 2,112,127 | $37.8M |
| vanguard capital management llc | 1,667,826 | $29.8M |
| rtw investments, lp | 1,592,043 | $28.5M |
| ra capital management, l.p. | 1,503,084 | $26.9M |
| baker bros. advisors lp | 996,351 | $17.8M |
| octagon capital advisors lp | 960,847 | $17.2M |
| avidity partners management lp | 937,132 | $17.2M |
Showing top 10 of 66 institutional holders of Aktis Oncology Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 16.3%
- Days to cover
- 8.1
- Shares short
- 2,570,690
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AKTS short interestFrequently asked questions
What is the AI investment thesis for Aktis Oncology Inc.?
Aktis Oncology Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for cancer, with lead programs in Nectin-4 and B7-H3 expressing tumors.
What is Aktis Oncology Inc.'s lead drug candidate?
Aktis Oncology Inc.'s most advanced tracked candidate is [225ac]ac-aky-1189 (Phase 1) for Urothelial Carcinoma Bladder.
Who is the CEO of Aktis Oncology Inc.?
Dr. Matthew Roden Ph.D. is the chief executive officer of Aktis Oncology Inc. (AKTS).
Where is Aktis Oncology Inc. headquartered?
Aktis Oncology Inc. (AKTS) is headquartered in Boston, MA, United States.
What therapeutic areas does Aktis Oncology Inc. focus on?
Aktis Oncology Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.